Coronavirus | Featured Stories

Pfizer: COVID Vaccine Safe And Effective For Kids 5-11

In this photo taken Wednesday, May 19, 2010, a sign in front of the Pfizer research and manufacturing facility in Pearl River, N.Y. Pfizer announced Tuesday that it would layoff 1250 people at the plant by 2014. The company will retain one research division at the site, employing 1,000. (AP Photo/Mark Lennihan)

Pfizer is touting the safety and effectiveness of its COVID vaccine on children over the age of five in lower dose.
The drug company announced the results of a trial involving kids ages five to eleven Monday morning.

It showed a lower dose of the vaccine, one-third the amount given to adults, led to a robust antibody response comparable to those in people ages 16 to 25 who received the full dose of the vaccine.
Those in the younger age group were given a lower dose of the vaccine, but it still included two shots administered three weeks apart.
Vaccine side effects were also similar and the government could approve the vaccine for kids ages 5-11 by November.
Pfizer Chairman and CEO Albert Bourla said the trial results “provide a strong foundation for seeking authorization of our vaccine for children five to eleven years old, and we plan to submit them to the FDA and other regulators with urgency.”